Compared with the controls, the levels of MAP3K4 expression by immunohistochemical staining were significantly elevated in the liver tissues of NAFLD patients (Fig. 4B). This evidence concerns the gene MAP3K4 and metabolic dysfunction-associated steatotic liver disease.